Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-25-046946
Filing Date
2025-03-28
Accepted
2025-03-28 17:19:15
Documents
14
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A aldx-20241231.htm   iXBRL 10-K/A 81682
2 EX-23.1 aldx-ex23_1.htm EX-23.1 3898
3 EX-31.1 aldx-ex31_1.htm EX-31.1 6070
4 EX-31.2 aldx-ex31_2.htm EX-31.2 6103
  Complete submission text file 0000950170-25-046946.txt   300817

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20241231.xsd EX-101.SCH 51828
16 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20241231_htm.xml XML 10220
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36332 | Film No.: 25787777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)